PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2017

Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury.

Mouse / Other

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 29126435 ↗2017Reported benefit

Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury.

MouseOtherC57BL/6n = n = 6 to 8 per group at postnatal day 7 and 14; n = 5 to 7…Intravenous (superficial temporal vein) or intratrachealSingle dose of 50,000, 75,000 or 100,000 cells per pup; 100…Early treatment 12 h after commencement of hyperoxia, or late treatment 4 days…

Model: Bronchopulmonary dysplasia model combining intra-amniotic lipopolysaccharide 0.1 ug in 5 ul per sac at embryonic day 16 with postnatal hyperoxia at FiO2 0.65 begun within 12 h of birth or at postnatal day 3.5, for 7, 14 or 28 days

A single dose of human amnion epithelial cells improved lung tissue-to-airspace ratio dose-dependently, with 75,000 and 100,000 cells effective by postnatal day 7, and intravenous and intratracheal routes were equally efficacious. Early and late treatment both restored septal crest density, lowered…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.